AAAAAA

   
Results: 1-9 |
Results: 9
PHASE-III STUDY OF TLC D-99 (LIPOSOME-ENCAPSULATED DOXORUBICIN) VS. FREE DOXORUBICIN (DOX) IN PATIENTS WITH METASTATIC BREAST-CANCER (MBC)
Authors: WINER E BATIST G HARRIS L HOOFTMAN L PARK Y
Citation: E. Winer et al., PHASE-III STUDY OF TLC D-99 (LIPOSOME-ENCAPSULATED DOXORUBICIN) VS. FREE DOXORUBICIN (DOX) IN PATIENTS WITH METASTATIC BREAST-CANCER (MBC), Annals of oncology, 9, 1998, pp. 590-590
PROBABILITY OF CARRYING A MUTATION OF BREAST-OVARIAN CANCER GENE BRCA1 BASED ON FAMILY HISTORY
Authors: BERRY DA PARMIGIANI G SANCHEZ J SCHILDKRAUT J WINER E
Citation: Da. Berry et al., PROBABILITY OF CARRYING A MUTATION OF BREAST-OVARIAN CANCER GENE BRCA1 BASED ON FAMILY HISTORY, Journal of the National Cancer Institute, 89(3), 1997, pp. 227-238
GENETIC TESTING FOR SUSCEPTIBILITY TO BREAST-CANCER - FINDINGS FROM WOMENS FOCUS GROUPS
Authors: TESSARO I BORSTELMANN N REGAN K RIMER BK WINER E
Citation: I. Tessaro et al., GENETIC TESTING FOR SUSCEPTIBILITY TO BREAST-CANCER - FINDINGS FROM WOMENS FOCUS GROUPS, Journal of women's health, 6(3), 1997, pp. 317-327
BRCA1 AND BRCA1 SEQUENCE-ANALYSIS OF 335 HIGH-RISK WOMEN
Authors: FRANK TS MANLEY S THOMAS A MCCLURE M WARD BE SHATTUCKEIDENS D OLIPHANT A ANTMAN K BERNHARDT B BUYS S CUMMINGS S EDGE S FARRELL C GARBER J ISAACS C LOADER S OFFIT K OLOPADE F PESHKIN B ROWLEY P RUSSO D STRONG L VENNE V WEBER B WINER E WOOD M WOOD WC SKOLNICK M
Citation: Ts. Frank et al., BRCA1 AND BRCA1 SEQUENCE-ANALYSIS OF 335 HIGH-RISK WOMEN, American journal of human genetics, 61(4), 1997, pp. 351-351
HYDROCORTISONE (HC) WITH OR WITHOUT MITOXANTRONE (M) IN PATIENTS (PTS) WITH HORMONE-REFRACTORY PROSTATE-CANCER (HRPC) - PRELIMINARY-RESULTSFROM A PROSPECTIVE RANDOMIZED CANCER AND LEUKEMIA GROUP-B STUDY (9182) COMPARING CHEMOTHERAPY TO BEST SUPPORTIVE CARE
Authors: KANTOFF PW CONAWAY M WINER E PICUS J VOGELZANG NJ
Citation: Pw. Kantoff et al., HYDROCORTISONE (HC) WITH OR WITHOUT MITOXANTRONE (M) IN PATIENTS (PTS) WITH HORMONE-REFRACTORY PROSTATE-CANCER (HRPC) - PRELIMINARY-RESULTSFROM A PROSPECTIVE RANDOMIZED CANCER AND LEUKEMIA GROUP-B STUDY (9182) COMPARING CHEMOTHERAPY TO BEST SUPPORTIVE CARE, Journal of clinical oncology, 14(5), 1996, pp. 2013-2013
RANDOMIZED COMPARISON OF VINORELBINE AND MELPHALAN IN ANTHRACYCLINE-REFRACTORY ADVANCED BREAST-CANCER
Authors: JONES S WINER E VOGEL C LAUFMAN L HUTCHINS L OROURKE M LEMBERSKY B BUDMAN D BIGLEY J HOHNEKER J
Citation: S. Jones et al., RANDOMIZED COMPARISON OF VINORELBINE AND MELPHALAN IN ANTHRACYCLINE-REFRACTORY ADVANCED BREAST-CANCER, Journal of clinical oncology, 13(10), 1995, pp. 2567-2574
FROM SAWDUST TO SINE WAVES + AMERICAN LUTHIERS SPEAR,ROBERT AND SPEAR,DEENA
Authors: WINER E
Citation: E. Winer, FROM SAWDUST TO SINE WAVES + AMERICAN LUTHIERS SPEAR,ROBERT AND SPEAR,DEENA, Strad, 105(1251), 1994, pp. 691
PREVENTION OF CHEMOTHERAPY-RELATED ANEMIA BY RECOMBINANT-HUMAN-ERYTHROPOIETIN (EPO) IN PATIENTS WITH SMALL-CELL LUNG-CANCER (SCLC) RECEIVING CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CAE) CHEMOTHERAPY WITHG-CSF SUPPORT
Authors: CRAWFORD J BLACKWELL S SHOEMAKER D PUPA MR MULHAUSEN T HERNDON J WINER E FLYNN J DEMPSEY H
Citation: J. Crawford et al., PREVENTION OF CHEMOTHERAPY-RELATED ANEMIA BY RECOMBINANT-HUMAN-ERYTHROPOIETIN (EPO) IN PATIENTS WITH SMALL-CELL LUNG-CANCER (SCLC) RECEIVING CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE (CAE) CHEMOTHERAPY WITHG-CSF SUPPORT, Blood, 84(10), 1994, pp. 10000129-10000129
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT AS CONSOLIDATION AFTER STANDARD-DOSE ADJUVANT THERAPY FOR HIGH-RISK PRIMARY BREAST-CANCER
Authors: PETERS WP ROSS M VREDENBURGH JJ MEISENBERG B MARKS LB WINER E KURTZBERG J BAST RC JONES R SHPALL E WU K ROSNER G GILBERT C MATHIAS B CONIGLIO D PETROS W HENDERSON IC NORTON L WEISS RB BUDMAN D HURD D
Citation: Wp. Peters et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT AS CONSOLIDATION AFTER STANDARD-DOSE ADJUVANT THERAPY FOR HIGH-RISK PRIMARY BREAST-CANCER, Journal of clinical oncology, 11(6), 1993, pp. 1132-1143
Risultati: 1-9 |